• Children Between 2 and 10
• Adults Over 55
  

  The MPSV4 vaccine is recommended for certain high risk children from the ages of 2 through 10 and high risk adults over 55. They include people who travel to, and United States citizens who reside in, countries where meningitis is hyperendemic or epidemic, persons with terminal complement deficiency (an immune system disorder) and persons with a damaged spleen or whose spleen has been removed. The number of doses needed depends on the person’s age. Ask your doctor for more details.
  

• Adolescents and Adults Age 11-55
  MCV4 is recommended for all children at their routine preadolescent visit (11 to 12 years of age). For those who have never gotten MCV4 previously, a dose is recommended at high school entry. MCV4 is the preferred vaccine for people 11 to 55 years of age, but MPSV4 can be used if MCV4 is not available.

Other adolescents who want to decrease their risk of meningococcal disease can also get the vaccine.

Meningococcal vaccine is also recommended for other people at increased risk for meningococcal disease, including:

• College freshmen living in dormitories.
• Microbiologists who are routinely exposed to meningococcal bacteria.
• U.S. military recruits.
• Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as parts of Africa.
• Anyone who has a damaged spleen, or whose spleen has been removed.
• Anyone who has terminal complement component deficiency (an immune system disorder).
• People who might have been exposed to meningitis during an outbreak.

Meningococcal conjugate vaccine may be given at the same time as other vaccines.